Your browser doesn't support javascript.
loading
Effect of Glucosamine on Intraocular Pressure and Risk of Developing Glaucoma.
Lehrer, Steven; Morello, Timothy; Karrasch, Charles; Rheinstein, Peter H; Danias, John.
Afiliação
  • Lehrer S; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai.
  • Morello T; SUNY Downstate College of Medicine Brooklyn.
  • Karrasch C; SUNY Downstate College of Medicine Brooklyn.
  • Rheinstein PH; Severn Health Solutions, Severna Park, MD.
  • Danias J; Department of Ophthalmology, SUNY Downstate HSU, New York, NY.
J Glaucoma ; 33(4): 240-245, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38031296
ABSTRACT
PRCIS Glucosamine supplementation is common but can be associated with increased intraocular pressure (IOP) and could contribute to the pathogenesis of glaucoma. It may be prudent for ophthalmologists to elicit any history of glucosamine use from their patients and advise them accordingly. Further studies on the role of glucosamine in glaucoma are warranted.

BACKGROUND:

The most frequently recommended slow-acting medication for osteoarthritis symptoms is glucosamine, although its effectiveness is questionable. Widely used glucosamine sulfate supplements may increase IOP.

METHODS:

In the current study, we analyzed online databases such as UK Biobank, MedWatch, and FinnGen to evaluate the relationship between glucosamine and IOP and glaucoma. We included budesonide and fluticasone in the analysis for comparison since these drugs are associated with increased IOP.

RESULTS:

In UK Biobank subjects, glucosamine use was associated with increased corneal compensated IOP ( P =0.002, 2-tailed t test). This was also true in subjects without glaucoma ( P =0.002, 2-tailed t test). However, no significant association between glucosamine and IOP was detected in subjects with a diagnosis of glaucoma. In MedWatch, 0.21% of subjects taking glucosamine reported glaucoma, 0.29% of subjects using budesonide reported glaucoma, and 0.22% of subjects using fluticasone reported glaucoma. In contrast, 0.08% of subjects using any other drug reported glaucoma. This variability is significant ( P <0.001, 2-tailed Fisher exact test). Data from FinnGen on the risk of primary open angle glaucoma or glaucoma in subjects using glucosamine before the diagnosis of the disease revealed a significantly increased risk for both primary open angle glaucoma (hazard ratio 2.35) and glaucoma (hazard ratio 1.95).

CONCLUSION:

Glucosamine supplementation is common but can be associated with increased IOP and could contribute to the pathogenesis of glaucoma. It may be prudent for ophthalmologists to elicit any history of glucosamine use from their patients and advise them accordingly. Further studies on the role of glucosamine in glaucoma are warranted.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glaucoma / Glaucoma de Ângulo Aberto Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glaucoma / Glaucoma de Ângulo Aberto Idioma: En Ano de publicação: 2024 Tipo de documento: Article